Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer

BACKGROUND: Colorectal cancer is the third most common cancer and the third leading cause of cancer-related death. Bevacizumab is a humanized monoclonal antibody developed against vascular endothelial growth factor (VEGF) for the treatment of metastatic cancer. The parameters of RECIST (Response Eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Bisgin, Atil, Kargi, Aysegul, Yalcin, Arzu D, Aydin, Cigdem, Ekinci, Deniz, Savas, Burhan, Sanlioglu, Salih
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359245/
https://www.ncbi.nlm.nih.gov/pubmed/22313795
http://dx.doi.org/10.1186/1471-2407-12-58

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359245/
https://www.ncbi.nlm.nih.gov/pubmed/22313795
http://dx.doi.org/10.1186/1471-2407-12-58

Ejemplares similares